2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Renal Replacement Therapy

Volumn 3, Issue 1, 2017, Pages

  Yamamoto, Hiroyasu ^a   Nishi, Shinichi ^b   Tomo, Tadashi ^c   Masakane, Ikuto ^d   Saito, Kazuhide ^e   Nangaku, Masaomi ^f   Hattori, Motoshi ^g   Suzuki, Takahiro ^h,i   Morita, Satoshi ^j   Ashida, Akira ^k   Ito, Yasuhiko ^l   Kuragano, Takahiro ^m   Komatsu, Yasuhiro ⁿ   Sakai, Ken ^o   Tsubakihara, Yoshiharu ^p,q   Tsuruya, Kazuhiko ^r   Hayashi, Terumasa ^s   Hirakata, Hideki ^t,u   Honda, Hirokazu ^v  

^a Atsugi City Hospital   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OITA UNIVERSITY HOSPITAL   (Japan)

^d Yabuki Hospital   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h JICHI MEDICAL UNIVERSITY   (Japan)

ⁱ KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k OSAKA MEDICAL COLLEGE   (Japan)

^l NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m HYOGO COLLEGE OF MEDICINE   (Japan)

ⁿ ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^o TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q Jikei University of Health Care Sciences   (Japan)

^r KYUSHU UNIVERSITY   (Japan)

^s OSAKA GENERAL MEDICAL CENTER   (Japan)

^t FUKUOKA RED CROSS HOSPITAL   (Japan)

^u Fukuoka Medical Clinic   (Japan)

^v SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

more..

Author keywords

Anemia; Chronic kidney disease; Erythropoietin stimulating agents; Guideline; Iron

Indexed keywords

EID: 85084378425     PISSN: None     EISSN: 20591381     Source Type: Journal    
DOI: 10.1186/s41100-017-0114-y     Document Type: Article

References (282)

1. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: Correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood. 1989;74:645-51.
2. Donnelly S. Why is erythropoietin made in the kidney The kidney functions as a critmeter. Am J Kidney Dis. 2001;38:415-25.
3. Urabe A, Mitani K, Yoshinaga K, et al. Serum erythropoietin titers in hematological malignancies and related diseases. Int J Cell Cloning. 1992;10:333-7.
4. Suzuki T, Oh I, Ohmine K, et al. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. Int J Hematol. 2015;101:32-6.
5. Fehr T, Ammann P, Garzoni D, et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004;66:1206-11.
6. Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant. 2007;22:2900-8.
7. Besarab A, Ayyoub F. Anemia in renal disease. Diseases of the kidney and urinary tract (R. Schrier). Philadelphia: Lippincott Williams and Wilkins; 2007. p. 2406-30.
8. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35:134-48.
9. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol. 2003;14:1776-84.
10. Means Jr RT, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood. 1991;78:2564-7.
11. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58:591-8.
12. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis. 2010;55:726-41.
13. Tsubakihara Y, (Japanese Society of Dialysis Therapy Working Group on Revision of Guidelines for Renal Anemia in Chronic Kidney Disease). Analysis of plasma erythropoietin level in predialysis patients with renal failure and renal anemia. Jpn J Nephrol. 2007;49:292.
14. Gejyo F, Saito A, Akizawa T, et al. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004;8:443-59.
15. Tsubakihara Y, Nishi S, Akiba, et al. 2008 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2010;14:240-75.
16. Hirasawa Y, Suzuki M, Itami N, et al. Maintenance hematocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin (rHuEPO) treatment (rHuEPO survey). J Jpn Soc Dial Ther. 2003;36:1265-72 (in Japanese).
17. Akizawa T, Pisoni RL, Akiba T, et al. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): Results from the DOPPS. Nephrol Dial Transplant. 2008;23:3643-53.
18. Inaba M, Hayashino Y, Shoji T, et al. Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: The Japan dialysis outcomes and practice pattern study. Nephron Clin Pract. 2012;120:c91-100.
19. Akizawa T, Saito A, Gejyo F, JET Study Group, et al. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial. 2014;18:404-13.
20. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-9.
21. Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol. 2008;3:1669-75.
22. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: A randomized trial. Clin J Am Soc Nephrol. 2009;4:726-33.
23. Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012;27:2418-25.
24. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis. Arch Intern Med. 2009;169:1104-12.
25. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82:235-41.
26. Akizawa T, Koshikawa S, Iwasaki M. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. Ther Apher Dial. 2007;11:220-6.
27. Fukuhara S, Akizawa T, Morita S, Koshikawa S. Quality of life improvements in dialysis patients receiving darbepoetin alfa. Ther Apher Dial. 2008;12:72-7.
28. Suzuki M, Bessho M. C.E.R.A. administered intravenously (IV) at extended administration intervals successfully maintains target hemoglobin (Hb) levels in Japanese patients with CKD on dialysis previously treated with recombinant human erythropoietin (EPO). Nephrol Dial Transplant Plus. 2008; (Suppl 2): Ii 151 (abstract SP367).
29. Japanese Society for Dialysis Therapy; Statistical Survey Committee. An overview of regular dialysis treatment in Japan (as of 31 December 2012). JSDT, 2012 (in Japanese).
30. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90.
31. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33.
32. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012; Suppl 2: 279-335.
33. Locatelli F, Barany P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346-59.
34. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1077-83.
35. Eriguchi R, Taniguchi M, Ninomiya T, et al. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: The Q-Cohort study. J Nephrol. 2015;28:217-25.
36. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32.
37. Maekawa K, Shoji T, Emoto M, et al. Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant. 2008;23:2329-36.
38. Lau JH, Gangji AS, Rabbat CG, Brimble KS. Impact of haemoglobin and erythropoietin dose changes on mortality: A secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant. 2010;25:4002-9.
39. Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008;51:62-70.
40. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-54.
41. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. Am J Kidney Dis. 2010;55:519-34.
42. Tsubakihara Y, Gejyo F, Nishi S, et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial. 2012;16:529-40.
43. Singh AK, Szczech L, Tang KL, CHOIR Investigators, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
44. Drueke TB, Locatelli F, Clyne N, CREATE investigators, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84.
45. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-8.
46. Suzuki M, Saito A, Gejyo F, et al. Baseline characteristics and anemia treatment for new hemodialysis patients. J Jpn Soc Dial Ther. 2008;41:251-4 (in Japanese).
47. Nangaku M, Imai E, Tsubakihara Y, Yamaya J, Akizawa T. Interim analysis results of survey on long-term use of darbepoetin alpha in non-dialysis CKD patients. Kidney and Dial. 2014;76:743-52 (in Japanese).
48. Nakayama M, Sato T, Miyazaki M, et al. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: The Gonryo study. Hypertens Res. 2011;34:1106-10.
49. Hirakata H, Nitta K, Tomo T, et al. Clinical guidelines for the evaluation and the treatment of cardiovascular complications in hemodialysis patients. J Jpn Soc Dial Ther. 2011;44:341-424 (in Japanese).
50. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-85.
51. Ritz E, Laville M, Bilous RW, Anemia Correction in Diabetes Study Investigators, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194-207.
52. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753-60.
53. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738-50.
54. Lewis EF, Pfeffer MA, Feng A, TREAT Investigators, et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: A randomized trial. Clin J Am Soc Nephrol. 2011;6:845-55.
55. Akizawa T, Gejyo F, Nishi S, KRN321 STUDY Group, et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: A randomized controlled study. Ther Apher Dial. 2011;15:431-40.
56. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 2004;65:1864-9.
57. Viglino G, Neri L, Barbieri S. Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy. Kidney Int. 2008; (Suppl.): S52-5.
58. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N. Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. 2003;64 Suppl 87:S6-11.
59. Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2011;6:1973-81.
60. Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S, KRN321 A09 Study Group. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients. Ther Apher Dial. 2008;12:19-27.
61. Kubota M, Hiramatsu M, Yamakawa M, KRN321 SCA10 Study Group, et al. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan. Clin Exp Nephrol. 2011;15:884-92.
62. Hiramatsu M, Hotta O, Masakane I, et al. Efficacy of subcutaneous and intravenous administration of long-acting erythropoiesis stimulating agent (CERA) in PD patients with renal anemia. Jpn Pharmacol Ther. 2011;39:569-79 (in Japanese).
63. González MT, Ramos R, Vera M, et al. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients. Ren Fail. 2013;35:314-9.
64. Bommer J, Barth HP, Zeier M, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol. 1991;88:136-43.
65. Zappacosta AR. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. Am J Med. 1991;91:229-32.
66. Tomson CRV, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1992;7:129-32.
67. Muirhead N, Churchill DN, Goldstein M, et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol. 1992;12:303-10.
68. Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin Nephrol. 1994;41:297-302.
69. Paganini EP, Eschbach JW, Lazarus JM, et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis. 1995;26:331-40.
70. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol. 1996;50:171-7.
71. Virot JS, Janin G, Guillaumie J, et al. Must erythropoietin be injected by the subcutaneous route for every hemodialysis patients Am J Kidney Dis. 1996;28:400-8.
72. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol. 1997;8:288-93.
73. De Schoenmakere G, Lameire N, Dhondt A, et al. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant. 1998;13:1770-5.
74. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med. 1998;339:578-83.
75. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439-46.
76. Hynes DM, Stroupe KT, Greer JW, et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med. 2002;112:169-75.
77. Leikis MJ, Kent AB, Becker GJ, McMahon LP. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Nephrology (Carlton). 2004;9:153-60.
78. Guideline 9. Route of administration of epoetin. Nephrol Dial Transplant. 1999;14 Suppl 5:S19-20.
79. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001;37(Suppl 1):S207-S11.
80. Locatelli F, Aljama P, Bárány P, Canaud B, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1-ii47.
81. KDOQI. Clinical practice guidelines and clinical recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47 Suppl 3:S9-145.
82. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-5.
83. Kim CD, Park SH, Kim DJ, et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. Nephrology (Carlton). 2009;14:482-7.
84. Bommer J, Asmus G, Wenning M, Bommer G. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: A German prospective, randomized, multicentre study. Nephrol Dial Transplant. 2008;23:4002-8.
85. Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney AP. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology (Carlton). 2005;10:129-35.
86. Aarup M, Bryndum J, Dieperink H, Joffe P. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant. 2006;21:1312-6.
87. Nagaya H, Inaguma D, Kitagawa A, et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clin Exp Nephrol. 2010;14:158-63.
88. Mann J, Kessler M, Villa G, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: A combined analysis of eight multicenter trials. Clin Nephrol. 2007;67:140-8.
89. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: A randomized trial. Am J Kidney Dis. 2007;50:989-1000.
90. Levin NW, Fishbane S, Cañedo FV, MAXIMA study investigators, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415-21.
91. Sulowicz W, Locatelli F, Ryckelynck JP, PROTOS Study Investigators, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637-46.
92. Spinowitz B, Coyne DW, Lok CE, RUBRA Study Investigators, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008;28:280-9.
93. Canaud B, Mingardi G, Braun J, STRIATA Study Investigators, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654-61.
94. Carrera F, Lok CE, de Francisco A, PATRONUS Investigators, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009-17.
95. Shimomura K, Mochizuki T, Watanabe Y, et al. Efficacy of epoetin beta pegol of different doses adjusted by changing administration intervals on improvement of anemia in hemodialysis patients. Kidney Dial. 2013;75:447-51 (in Japanese).
96. Kinugawa E, Yumita S, Sato T, et al. Dose response study of continuous erythropoietin receptor activator (C.E.R.A.) in patients with renal anemia on hemodialysis: A double-blind parallel-group trial. Jpn Pharm Ther. 2011;39(Suppl):S9-19 (in Japanese).
97. Mizuguchi T, Sakurai Y, Ishida N, et al. Randomized double-blind study of C.E.R.A. compared with rHuEPO in hemodialysis patients. Jpn J Clin Dial. 2011;27:723-36 (in Japanese).
98. Toida T, Sato Y, Shibata N, Kitamura K, Fujimoto S. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purif. 2014;38:174-9.
99. Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: A randomized study. Ther Apher Dial. 2014;18:421-6.
100. Akazawa T, Suzuki K, Suzuki Y. Comparison of pain caused by change in fluid volume of darbepoetin-a in predialysis chronic kidney disease patients. Med Drug J. 2013;49:157-63 (in Japanese).
101. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006;368:947-53.
102. Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010;55:639-47.
103. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009;4:57-61.
104. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med. 1997;87:710-3.
105. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004;22:112-23.
106. Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62:860-73.
107. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:1416-23.
108. Mitsuiki K, Harada A, Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: Investigation of cutoff values for reticulocyte hemoglobin content. Clin Exp Nephrol. 2003;7:52-7.
109. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant. 2003;18:370-7.
110. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30:912-22.
111. Fishbane S, Galgano C, Langley Jr RC, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217-22.
112. Bovy C, Gothot A, Delanaye P, Warling X, Krzesinski JM, Beguin Y. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: Sensitivity and specificity. Nephrol Dial Transplant. 2007;22:1156-62.
113. Fishbane S, Lynn RI. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis. 1995;25:426-32.
114. Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol. 2002;58:363-9.
115. Beerenhout C, Bekers O, Kooman JP, van der Sande FM, Leunissen KM. A comparison between the soluble transferrin receptor, transferrin saturation and serum ferritin as markers of iron state in hemodialysis patients. Nephron. 2002;92:32-5.
116. Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25:3996-4002.
117. Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32:439-46.
118. Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int. 2009;75:104-10.
119. Ferrucci L, Semba RD, Guralnik JM, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010;115:3810-6.
120. Bross R, Zitterkoph J, Pithia J, et al. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol. 2009;29:571-81.
121. Mizuguchi T, Okada K, Mizuguchi J, Kawashima S. Circadian variation of iron metabolism marker in hemodialysis patients. Jpn J Jpn Soc Dial Ther. 2010;43:493-9 (in Japanese).
122. Kroot JJ, Hendriks JC, Laarakkers CM, et al. Pre-analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: Implications for clinical studies. Anal Biochem. 2009;389:124-9.
123. Morrison B, Shenkin A, McLelland A, et al. Intra-individual variation in commonly analyzed serum constituents. Clin Chem. 1979;25:1799-805.
124. Nicolau GY, Haus E, Lakatua DJ, et al. Circadian periodicity of the results of frequently used laboratory tests in elderly subjects. Endocrinologie. 1983;21:3-21.
125. Coyne DW, Kapoian T, Suki W, DRIVE Study Group, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975-84.
126. Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65:1091-8.
127. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:77-83.
128. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89:87-93.
129. Rostoker G, Griuncelli M, Loridon C, et al. Reassessment of iron biomarkers for prediction of dialysis iron overload: An MRI study. PLoS One. 2015;10:e0132006.
130. Druëke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-7.
131. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 2005;46:255-64.
132. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One. 2012;7:e50295.
133. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822. doi: 10.1136/bmj.f4822.
134. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24:1151-8.
135. Goddard AF, James MW, McIntyre AS, Scott BB, British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60:1309-16.
136. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86:845-54.
137. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;Suppl 2:S279-S335.
138. Hasuike Y, Nonoguchi H, Tokuyama M, et al. Serum ferritin predicts prognosis in hemodialysis patients: The Nishinomiya study. Clin Exp Nephrol. 2010;14:349-55.
139. Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int. 2015;5(1):23-32.
140. Kovesdy CP, Estrada W, Ahmadzadeh S, Kalantar-Zadeh K. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:435-41.
141. Ichii H, Masuda Y, Hassanzadeh T, Saffarian M, Gollapudi S, Vaziri ND. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol. 2012;36:50-7.
142. Sonnweber T, Theurl I, Seifert M, et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant. 2011;26:977-87.
143. Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: Expanding spectrum. Int J Infect Dis. 2007;11:482-7.
144. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869-76.
145. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant. 1989;4:883-7.
146. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant. 1995;10:377-81.
147. Galić G, Tomić M, Galesić K, et al. The etiological relation between serum iron level and infection incidence in hemodialysis uremic patients. Coll Antropol. 2011;35:93-101.
148. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012;1:CD007857.
149. Qiao L, Feng Y. Intakes of heme iron and zinc and colorectal cancer incidence: A meta-analysis of prospective studies. Cancer Causes Control. 2013;24:1175-83.
150. Charytan C, Qunibi W, Bailie GR, Group VCS. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55-62.
151. Liles AM. Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease. Am J Health Syst Pharm. 2012;69:1206-11.
152. Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB, United States Iron Sucrose (Venofer) Clinical Trials Group. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: A randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:475-82.
153. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:386-93.
154. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41-6.
155. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif. 2008;26:151-6.
156. Adhikary L, Acharya S. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. JNMA J Nepal Med Assoc. 2011;51:133-6.
157. Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int. 2008;28:149-54.
158. Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein M. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol. 2007;2:688-93.
159. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-8.
160. Brasse-Lagnel C, Karim Z, Letteron P, Bekri S, Bado A, Beaumont C. Intestinal DMT1 cotransporter is downregulated by hepcidin via proteasome-internalization and degradation. Gastroenterology. 2011;140:1261-71.
161. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation. Am J Nephrol. 2010;31:534-40.
162. Sasaki Y, Noguchi-Sasaki M, Matsuo-Tezuka Y, et al. Epoetin beta pegol (C. E. R. A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol. 2014;99:561-9.
163. Singh A. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: A review of the evidence. Semin Dial. 2009;22:64-9.
164. Yahiro M, Kuragano T, Kida A, et al. The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients. Clin Exp Nephrol. 2012;16:448-55.
165. Schiesser D, Binet I, Tsinalis D, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant. 2006;21:2841-5.
166. Canavese C, Bergamo D, Ciccone G, et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant. 2004;19:1564-70.
167. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070-80.
168. Japanese Society for Dialysis Therapy. JSDT guidelines for the treatment of hepatitis C virus infection in dialysis patients. Jpn J Jpn Soc Dial Ther. 2011;44:481-531. in Japanese.
169. Solomon SD, Hajime U, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146-55.
170. Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: Results from the RISCAVID study. Nephrol Dial Transplant. 2011;26:2641-8.
171. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17 Suppl 11:39-43.
172. Locatelli F, Aljama P, Bárány P, European Best Practice Guidelines Working Group, et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1-47.
173. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
174. McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013;37:549-58.
175. Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: A metaregression analysis. Am J Kidney Dis. 2013;61:44-56.
176. Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: Results from a cohort study from the registry in Japan. Am J Kidney Dis. 2012;59:108-16.
177. Kusano E, Akimoto T. Hematological issues associated with erythropoietin use and high-pressure dialysis therapy. Jpn Clin Dial. 1998;14:1139-48 (in Japanese).
178. Kyowa Hakko Kirin C0., Ltd. Drug interview form. Long-acting erythropoiesis stimulating agent, NESP® injection. http://www.kksmile.com/druginfo/interv/nesp_vc_in.pdf (in Japanese).
179. Chugai Pharmaceutical Co., Ltd. Drug interview form, Long-acting erythropoiesis stimulating agent, Mircera® injection syringe. https://chugai-pharm.jp/hc/ss/pr/drug/mir_sin0050/if/PDF/mir_if.pdf (in Japanese).
180. Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure evaluation in hemodialysis patients treated with erythropoietin. Am J Med. 1993;94:401-6.
181. Kuriyama S, Tomonari H, Tokudome G, et al. Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: A preliminary report. Hypertens Res. 2001;24:501-5.
182. KDIGO. Clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2:299-319.
183. Iseki K, Nishime K, Uehara H, et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron. 1996;72:30-6.
184. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortarity and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381-8.
185. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-24.
186. Suzuki M, Saito A, Shimojyo F, et al. Patient background and actual state of anemia treatment in new hemodialysis patients. J Jpn Soc Dial Ther. 2008;41:251-4 (in Japanese).
187. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-75.
188. Summary of PRCA case reports. As of October 31, 2002 http://www.evaluategroup.com/Universal/View.aspxtype=Story&id=36689.
189. Cournoyer D, Toffelmire EB, Wells GA, Canadian PRCA Focus Group, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk. J Am Soc Nephrol. 2004;15:2728-34.
190. Shinohara K, Mitani N, Miyazaki M, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-b, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78:15-20.
191. Shimizu H, Saitoh T, Ota F, et al. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126:114-8.
192. Shinohara K. Pure red cell aplasia caused by antibody to erythropoietin successfully treated by cyclosporine administration. Am J Hematol. 2007;82:247-8.
193. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant. 2007;22:1462-4.
194. Jacob A, Sandhu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant. 2006;21:2963-5.
195. Praditpornsilpa K, Tiranathagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88-92.
196. Tang YD, Hasan F, Giordano FJ, et al. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: Results of a double-blind, placebo-controlled, randomized trial. Am Heart J. 2009;158:941.
197. Hasegawa T, Elder SJ, Bragg-Gresham JL, et al. Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol. 2008;3:1373-8.
198. Nayak B, McCormick B. Erythropoietin use in CKD patients with cancer: To tread with caution J Nephrol. 2013;26:829.
199. Hazzan AD, Shah HH, Hong S, et al. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. Kidney Int. 2014;86:34-9.
200. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301-15.
201. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28:4996-5010.
202. Seliger SL, Zhang AD, Weir MR, et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011;80:288-94.
203. Imai E, Yamamoto R, Suzuki H, Watanabe T. Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin Exp Nephrol. 2010;14:445-52.
204. Lawler EV, Bradbury BD, Fonda JR, Gaziano JM, Gagnon DR. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol. 2010;5:667-72.
205. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2001;4:CD003266.
206. Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014;3:CD009297.
207. Carson JL, Grossman BJ, Kleinman S, Clinical Transfusion Medicine Committee of the AABB, et al. Red blood cell transfusion: A clinical practice guideline from the AABB*. Ann Intern Med. 2012;157:49-58.
208. Ministry of Health, Labour and Welfare. Guidelines for the use of blood products (revised) 2005.
209. Seliger S, Fox KM, Gandra SR, et al. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: A propensity-matched observational study. Clin J Am Soc Nephrol. 2010;5:882-8.
210. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042.
211. USRDS System. USRDS 2010 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health 2010, National Institute of Diabetes and Digestive and Kidney Diseases.
212. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant. 2004;4:438-43.
213. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation. 2005;80:1194-7.
214. Japanese Red Cross Society. Package insert for RBC concentrates, 2009 leukocytes reduced. http://www.jrc.or.jp/vcms_lf/iyakuhin_seihin_tenpu_ir-rcc-lr090805.htm.
215. Balasubramaniam GS, Morris M, Gupta A, Mesa IR, Thuraisingham R, Ashman N. Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. Transplantation. 2012;93:418-22.
216. Atkinson MA, Martz K, Warady BA, Neu AM. Risk for anemia in pediatric chronic kidney disease patients: A report of NAPRTCS. Pediatr Nephrol. 2010;25:1699-706.
217. World Health Organization. Worldwide prevalence of anemia 1993-2005: WHO global database on anaemia. In: De Benoist B, McLean E, Egli I and M Cogswell (eds). 2008.
218. Tanaka T, Yamashita A, Ichihara K. Reference intervals of clinical tests in children determined by latent reference value extraction method. J Jpn Pediatr Soc. 2008;112:1117-32 (in Japanese).
219. Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol. 2014;29:1493-505.
220. Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 2003;18:1055-62.
221. Mitsnefes MM, Kimball TR, Kartal J, et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr. 2006;149:671-5.
222. Gerson A, Hwang W, Fiorenza J, for the Council on Pediatric Nephrology and Urology of New York/New Jersey and the Kidney and Urology Foundation of Anemia, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis. 2004;44:1017-23.
223. Borzych-Duzalka D, Bilginer Y, Ha IS, For the International Pediatric Peritoneal Dialysis Network (IPPN) Registry, et al. Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol. 2013;24:665-76.
224. Atkinson MA, Furth S. Anemia in children with chronic kidney disease. Nat Rev Nephrol. 2011;7:635-41.
225. Koshy SM, Geary DF. Anemia in children with chronic kidney disease. Pediatr Nephrol. 2008;23:209-19.
226. Baracco R, Saadeh S, Valentini R, Kapur G, Jain A, Mattoo TK. Iron deficiency in children with early chronic kidney disease. Pediatr Nephrol. 2011;26:2077-80.
227. Kennedy SE, Mackie FE, Rosenberg A, McDonald SP. Waiting time and outcome of kidney transplantation in adolescents. Transplantation. 2006;82:1046-50.
228. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62:849-59.
229. van Stralen KJ, Krischock L, Schaefer F, et al. Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol Dial Transplant. 2012;27:3950-7.
230. Bamgbola O. Resistance to erythropoietin-stimulating agents: Etiology, evaluation, and therapeutic considerations. Pediatr Nephrol. 2012;27:195-205.
231. Domellof M. Iron requirements, absorption and metabolism in infancy and childhood. Curr Opin Nutr Metab Care. 2007;10:329-35.
232. North American Pediatric Renal Transplant Cooperative Study registry report. https://web.emmes.com/study/ped/annlrept/annlrept2004.pdf: 2004.
233. North American Pediatric Renal Trials and Collaborative Studies: (NAPRTCS) 2011 annual dialysis report. https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
234. Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2006;21:1144-52.
235. De Palo T, Giordano M, Palumbo F, et al. Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol. 2004;19:337-40.
236. Hattori M, Matsunaga A, Akioka Y, et al. Darbepoetin alfa for the treatment of anemia in children undergoing peritoneal dialysis: A multicenter prospective study in Japan. Clin Exp Nephrol. 2013;27:582-8.
237. Hattori M, Uemura O, Hataya H, The KRN321 Pediatric Study Group, et al. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: A multicenter prospective study in Japan. Cli Exp Nephrol. 2014;18:634-41.
238. Cano F, Alarcon C, Azocar M, et al. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol. 2011;26:1303-10.
239. Wedekin M, Ehrich JH, Pape L. Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta. Pediatr Transplant. 2011;15:329-33.
240. Watanabe Y, Itami N, Hashimoto N, et al. Efficacy of intravenous continuous erythropoietin receptor activator (CERA) for anemia correction in patients with renal anemia on hemodialysis-phase III clinical trial. Jpn Pharmacol Ther. 2011;39:S21-30 (in Japanese).
241. Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009;24:571-9.
242. Brandt JR, Avner ED, Hickman RO, Watkins SL. Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol. 1999;13:143-7.
243. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Eng J Med. 2004;351:1403-8.
244. Verheist D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet. 2004;363:1768-71.
245. Andrade J, Taylor PA, Love JM, Levin A. Successful reintroduction of a different erythropoietin-stimulating agent after pure red cell aplasia: Relapse after successful therapy with prednisone. Nephrol Dial Transplant. 2005;20:2548-51.
246. The Japan Society for Transplantation Factbook (The Japan Society for Transplantation, http://www.asas.or.jp/jst/pdf/factbook/factbook2011.pdf) (in Japanese).
247. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in kidney transplant recipients: A European survey. Am J Transplant. 2003;3:835-45.
248. Shibagaki Y, Shetty A. Anaemia is common after kidney transplantation, especially among African Americans. Nephrol Dial Transplant. 2004;19:2368.
249. Kadambi PV, Javaid B. Cardiovascular diseases in kidney transplant recipients: The role of anemia. Adv Chronic Kidney Dis. 2004;11:328.
250. Zadrazil J, Horak P, Horcicka V, Zahalkova J, Strebl P, Hruby M. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients. Kidney Blood Press Res. 2007;30:108-16.
251. Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients- A prospective cohort study. Am J Transplant. 2007;7:818.
252. Unal A, Sipahioglu MH, Akcakaya M, et al. An underappreciated problem in renal transplant recipients: Anemia. Transplant Proc. 2008;40:1399-403.
253. Heinze G, Kainz A, Hörl WH, Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ. 2009;339:b4018.
254. Molnar MZ, Mucsi I, Macdougall IC, et al. Prevalence and management of anaemia in renal transplant recipients: Data from ten European centres. Nephron Clin Pract. 2011;117:c127-34.
255. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000;11 Suppl 15:S1-86.
256. Capenko S, Lozireva S, Folkmane I, Bernarde K, Rosentals R, Murovska M. Anemia as a complication of a parvovirus B infection in renal transplant recipients. Medicina. 2012;48:299-304.
257. Chhabra D, Grafals M, Skaro AI, et al. Impact of anemia after renal transplantation on patients and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol. 2008;3:1168.
258. Kasiske BL, Zeier MG, Craig JC, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155.
259. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 9.1. Haematological complications. Anaemia. Nephrol Dial Transplant. 2002;17 Suppl 4:48-9.
260. Mohiuddin MK, El-Asir L, Gupta A, et al. Perioperative erythropoietin efficiency in renal transplantation. Transplant Proc. 2007;39:132-4.
261. Martinez F, Kamar N, Pallet N, NeoPDGF Study Investigators, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant. 2010;10:1695-700.
262. Chadban S, Baines L, Polkinghome K, et al. Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis. 2007;49:301-9.
263. Molnar MZ, Czira ME, Rudas A, et al. Association between the malnutrition-inflammation score and post-transplant anaemia. Nephrol Dial Transplant. 2011;26:2000-6.
264. Choukroun G, Kamar N, Dussol B, CAPRIT Study Investigators, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360-8.
265. Ishibashi M. Effect of dialysis vintage on outcomes of living- A nd deceased-donor renal transplantations. J Jpn Transplant. 2012;47:205-18 (in Japanese).
266. Goldfarb AG, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant. 2005;20:167-75.
267. Tsai JP, Lian JD, Wu SW, et al. Long term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg. 2011;35:2818-25.
268. Winkelmayer WC, Chandraker A, Alan Brookhart M, Kramar R, Sunder-Plassmann G. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006;21:3559-66.
269. Lorenz M, Winkelmayer WC, Horl WH, Sunder-Plassmann G. Anaemia after renal transplantation. Eur J Clin Invest. 2005;35 Suppl 3:89-94.
270. Iwamoto H, Nakamura Y, Konno O, et al. Correlation between post kidney transplant anemia and kidney graft function. Transplant Proc. 2014;46:496-8.
271. Webstar AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and evelolimus) for primary immunosuprresion of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234-48.
272. Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus-is iron the missing link Nephrol Dial Transplant. 2010;25:1667-75.
273. Sanchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc. 2007;39:2242-4.
274. Zheng S, Coyne DW, Joist H, et al. Iron deficiency anemia and iron losses after renal transplantation. Transplant Int. 2009;22:434-40.
275. Przybylowski P, Malyszko J, Glowinska I, Malyszko J, Kozlowska S, Mysliwiec M. Prevalence of iron deficiency in heart and kidney allograft recipients. Transplant Proc. 2011;43:3885-7.
276. Mudge DW, Tan KS, Miles R, et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation. 2012;93:822-6.
277. Pankewycz O, Kulaylat M, Fagan L, et al. A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. Transplant Proc. 2010;42:3537-41.
278. Sanchez-Fructuoso AI, Ruiz JC, Torregrosa JV, et al. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: The AnemiaTrans Study. Adv Ther. 2012;29:979-91.
279. Costa NA, Kshirsager AV, Wang L, Detwiler RK, Brookhart MA. Pretransplant erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality. Transplantation. 2013;96:807-13.
280. Watanabe K, Kageoka T. About reference ranges, Miwa's hematology, 3rd edition. Asano S, Ikeda Y, Uchiyama T (Eds.). Tokyo: Bunkodo Co., Ltd., 2006; 2017-7.
281. National Astronomical Observatory of Japan. Reference value of blood cells. In: Chronological scientific tables (2002). Tokyo: Maruzen Co., Ltd; 2001. p. 888.
282. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3):S9-S145.